stockrow
Friday 6 November 2026
Export STVN’s income statement to Excel — free account
Stevanato Group S.p.A.
STVN Healthcare Medical Instruments & Supplies
Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.
- Revenue
- +5.91%
- EPS
- +17.5%
- Free cash flow
- +4,089.9%
- Total debt
- +2.85%
Quarter to September 2026, against a year earlier
13.51
0.30
+2.27%
Follow STVN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
34.69 | 23.31 | 32.27 | 35.78 |
P/S ratio |
4.09 | 2.70 | 3.46 | 3.96 | |
P/FCF ratio |
376.13 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
55.32 | 42.49 | 135.30 | 88.04 | |
P/B ratio |
3.27 | 2.10 | 2.74 | 3.12 | |
Price to Tangible BV |
3.47 | 2.22 | 2.90 | 3.31 | |
EV/Sales |
4.37 | 2.97 | 3.75 | 4.24 | |
EV/EBITDA |
18.04 | 12.14 | 15.66 | 17.46 | |
EV/Operating CF |
18.12 | 13.49 | 18.81 | 21.20 | |
EV/FCF |
401.67 | (405.99) | (154.15) | (697.38) | |
Quick Ratio |
0.92 | 0.81 | 0.78 | 0.89 | |
Current Ratio |
1.76 | 1.63 | 1.61 | 1.73 | |
Net Debt/EBITDA |
3.54 | 5.21 | 5.60 | 4.07 | |
Debt/Assets |
18.51% | 17.50% | 17.04% | 17.75% | |
Debt/Equity |
0.32 | 0.30 | 0.29 | 0.30 | |
Asset Turnover |
0.50 | 0.51 | 0.50 | 0.49 | |
Operating CF/Net income |
1.82 | 2.69 | 1.37 | 1.35 | |
Capex/Depreciation |
(3.93) | (2.86) | (2.71) | (1.38) | |
Interest Coverage |
38.01 | 13.57 | 19.66 | 23.63 | |
Research and Development Expense of Revenue |
1.68% | 2.14% | 2.06% | 1.88% | |
Selling, General and Administrative Expense of Revenue |
10.04% | 11.70% | 10.51% | 9.68% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.02) | (0.04) | (0.03) | (0.02) | |
Graham Number |
8.97 | 9.33 | 9.12 | 9.41 | |
Earnings Yield |
2.88% | 4.29% | 3.10% | 2.79% | |
Free Cash Flow Yield |
0.27% | (0.27%) | (0.70%) | (0.15%) | |
Revenue per Share |
1.46 | 1.17 | 1.29 | 1.37 | |
Operating CF per Share |
0.36 | 0.32 | 0.13 | 0.24 | |
Capex per Share |
(0.37) | (0.30) | (0.28) | (0.15) | |
Free Cash Flow per Share |
0.00 | 0.02 | (0.14) | 0.09 | |
Cash per Share |
0.59 | 0.52 | 0.40 | 0.53 | |
Shareholders Equity per Share |
6.16 | 6.56 | 6.60 | 6.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.16 | 6.56 | 6.60 | 6.72 | |
Free Cash Flow |
(0.78) | 5.87 | (39.13) | 25.25 | |
Working Capital |
461.01 | 414.43 | 412.15 | 465.54 | |
Capital Expenditures |
(100.05) | (82.48) | (75.59) | (39.84) | |
Net Current Asset Value |
(129.10) | (162.26) | (158.32) | (132.01) | |
EV/EBIT |
26.07 | 17.71 | 23.01 | 25.54 | |
Capex to Sales |
0.25 | 0.26 | 0.22 | 0.11 | |
Price to Operating Income |
24.42 | 16.06 | 21.25 | 23.87 | |
| Other line items | |||||
Average Receivables |
398.17 | 357.94 | 381.78 | 391.87 | |
Average Payables |
273.95 | 270.64 | 275.89 | 263.62 | |
Average Inventory |
284.42 | 310.09 | 335.20 | 334.09 | |
Average Assets |
2,699.13 | 2,736.31 | 2,856.99 | 2,946.12 | |
Average Common Equity |
1,600.77 | 1,641.67 | 1,694.42 | 1,757.37 |
Columns are period end dates · fundamentals updated 5 Nov 2026